The global functional dyspepsia drug market size surpassed USD 10,500 million in 2024 and is predicted to reach around USD 16,940 million by 2034, registering a CAGR of 4.9% from 2024 to 2034.
The functional dyspepsia drug market refers to the production, distribution, and application of these drugs for functional dyspepsia which is a term for recurring symptoms of an upset stomach that have no obvious cause. It is also called non-ulcer dyspepsia. Drugs like lansoprazole, omeprazole, pantoprazole, rabeprazole, and esomeprazole are used to treat functional dyspepsia. This drug is used to treat heartburn, acidity, and gastroesophageal reflux disease a condition where the acid in the stomach flows back up into the food pipe (esophagus). There is a high demand for these drugs in gastric anticancer drugs and prokinetic drugs due to a growing number of cases, which is propelling market expansion.
However, the restraining factors of the market include regulatory complexities, changing raw material costs, high initial investment, and supply chain disruptions that can slow down the growth of the market. The future scope of the market includes supportive regulatory frameworks, increasing demand for applications, advancements in technology, strategic collaboration to maintain competitiveness, and increasing focus and investment in research and development that will help the growth of the functional dyspepsia drug market.
Published by Deepa Pandey
